Clinical trials: Drug Resistant Epilepsy
Epilepsy
Use of the Atkins Diet for Adults With Intractable Epilepsy
This is a prospective study to determine whether the Atkins diet reduces seizures, creates ketosis, and is well tolerated in adults with epilepsy.
- Trial name
- NCT00121927
- Testing
- Atkins diet (15 grams/day carbohydrates)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Epilepsy
ESIS in Pediatric DRE
The main reason for this research study is to gain information about how the brain makes seizures by causing seizures using very small amounts of current, or electrical stimulation.
- Trial name
- NCT05469373
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Sarah Katie Ihnen
Epilepsy
Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study
The purpose of this study is to determine whether omega-3 is effective in the treatment of medically intractable epilepsy as adjunctive therapy.
- Trial name
- NCT02899741
- Testing
- Omega-3
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Epilepsy
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
Background: The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier.
- Trial name
- NCT02531880
- Testing
- Mangafodipir, Gadolinium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Refractory Epilepsy
Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy
Evaluate the long-term clinical effectiveness and safety of the PINS vagus nerve stimulator to patients with refractory epilepsy.
- Trial name
- VNSRE (NCT02378792)
- Testing
- Vagus Nerve Stimulation
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Epilepsy, Drug Resistant, Acupuncture Therapy
Effectiveness and Safety of Thread Embedding Acupuncture for Drug Resistant Epilepsy
Epilepsy is one of the most common neurological diseases all over the world. Currently, about 70 million people have epilepsy worldwide.
- Trial name
- NCT04673071
- Testing
- Thread Embedding Acupuncture (TEA)
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Epilepsy
Hybrid Micro-macro Electrodes in Patients With Epilepsy
The aim of the MicroEPI study is to know whether it is possible to use safely a medical device (a micro-electrode) that allows recording the activity of neurons in the human brain.
- Trial name
- MicroEPI (NCT05335187)
- Testing
- micro-macro electrode implantation
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Pierre Mégevand
Refractory Epilepsy in Children
Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?
Clinical randomized controlled observer blinded add-on design. Additionally there will be a non-controlled follow-up phase of the study.
- Trial name
- NCT01378611
- Testing
- Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA
- Where
- 2 sites in Netherlands
- Volunteers
- 45 people
- Sponsor
- Epilepsiecentrum Kempenhaeghe
Partial Epilepsy
Multimodal Imaging in Pre-surgical Evaluation of Epilepsy
Epilepsy is the most common chronic neurological disorder in the world, affecting more than 50 million people worldwide. Approximately 35% of patients with epilepsy are refractory to all available antiepileptic drugs.
- Trial name
- EPIMAGE (NCT01735032)
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
- Trial name
- NCT04457687
- Testing
- Lorcaserin
- Where
- 22 sites in United States, Canada
- Sponsor
- Eisai Inc.
CDKL5 Deficiency Disorder
Efficacy and Safety Evaluation of Hyperthermic Baths in the Treatment of Seizures in CDKL5 Deficiency Disorder
The primary objective of this research is to study the efficacy and safety of hyperthermic baths as adjunctive therapy for reducing the frequency of seizures in CDKL5 deficiency.
- Trial name
- NCT06447675
- Testing
- Hyperthermic Baths
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Xuanwu Hospital, Beijing
Drug-resistant Partial Epilepsy
National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies
Sudden unexpected death in epilepsy (SUDEP) is the main concern of professionals and patient associations involved in epilepsy. These represent a priority for the Ligue Française Contre l'Epilepsie (LFCE).
- Trial name
- REPOMSE (NCT02572297)
- Testing
- video-EEG
- Where
- France
- Volunteers
- 1,072 people
- Sponsor
- Hospices Civils de Lyon
Drug Resistant Epilepsy
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy
This study aims at investigating the possible efficacy and safety of N-acetyl cysteine as adjuvant therapy in the treatment of drug-resistant epilepsy
- Trial name
- NCT05485558
- Testing
- N-acetyl cysteine, NAc
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Epilepsy, Alzheimer Disease
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Trial name
- NCT07222878
- Testing
- NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroPro Therapeutics, Inc.